The FDA approved the first drug in its class that targets moderate to severe acute pain in adults, without being addictive ...

There is good news for those with acute pain, as the FDA has approved a first-of-its-kind pain medication, and it’s one ...

This new drug is a non-opioid analgesic, the first of its kind, designed to treat moderate to severe acute pain in adults. Journavx works by targeting a pain-signaling pathway involving sodium ...

Mitochondrial dysfunction is increasingly considered as a critical contributor to the occurrence and progression of acute kidney injury (AKI ... Accumulating evidence has demonstrated the important ...

“Journavx works through a different pathway upstream of that, working before the pain signal even reaches the ... it could act as a safer medication overall for acute pain,” McKay said. During its ...

His doctors said “the pope is fine” and “working,” though they cautioned he remains in significant danger as he fights a bout ...

Researchers from Carnegie Mellon University and Allegheny Health Network have developed a new method for deep brain ...

On January 30, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid ...

One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which ...

The Phase IIa results continue a surge of momentum in a treatment space that last week saw the approval of Vertex’s Journavx as the first novel mechanism for acute pain in decades.

The Food and Drug Administration approved the pill from Vertex Pharmaceuticals for acute pain that often occurs after surgery or injuries. It's the first new pharmaceutical approach to treating pain ...